{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:36:54Z","timestamp":1792672614301,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007188","name":"Uniformed Services University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003896","name":"Henry M. Jackson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.vaccine.2018.11.052","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:50:09Z","timestamp":1544057409000},"page":"516-523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB\/c mice against a Leishmania major challenge"],"prefix":"10.1016","volume":"37","author":[{"given":"Ines","family":"Lakhal-Naouar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Koles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangala","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine B.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1913-3909","authenticated-orcid":false,"given":"Carl R.","family":"Alving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi E.","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.11.052_b0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/eri.10.19","article-title":"Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis","volume":"8","author":"Goto","year":"2010","journal-title":"Expert Rev Anti-Infect Therapy"},{"key":"10.1016\/j.vaccine.2018.11.052_b0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis: current status of vaccine development","volume":"14","author":"Handman","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2018.11.052_b0015","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1016\/j.vaccine.2005.02.015","article-title":"Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis","volume":"23","author":"Khamesipour","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.052_b0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/mi.2010.55","article-title":"Topical immunization strategies","volume":"3","author":"Czerkinsky","year":"2010","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm0103-99","article-title":"Can needle-free administration of vaccines become the norm in global immunization?","volume":"9","author":"Levine","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.11.052_b0030","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1517\/13543784.8.6.797","article-title":"Advances in vaccine delivery: transcutaneous immunisation","volume":"8","author":"Glenn","year":"1999","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.vaccine.2018.11.052_b0035","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/82225","article-title":"Transcutaneous immunization: a human vaccine delivery strategy using a patch","volume":"6","author":"Glenn","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.11.052_b0040","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.vaccine.2013.03.022","article-title":"Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery","volume":"31","author":"Matsuo","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.052_b0045","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.vaccine.2011.12.130","article-title":"Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria","volume":"30","author":"Hirobe","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.052_b0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jconrel.2012.04.001","article-title":"Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza","volume":"160","author":"Matsuo","year":"2012","journal-title":"J Controlled Release: Off J Controlled Release Soc"},{"key":"10.1016\/j.vaccine.2018.11.052_b0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.biomaterials.2015.04.007","article-title":"Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch","volume":"57","author":"Hirobe","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.vaccine.2018.11.052_b0060","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/36014","article-title":"Skin immunization made possible by cholera toxin","volume":"391","author":"Glenn","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.11.052_b0065","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1016\/j.vaccine.2011.05.085","article-title":"The influence of molecular adjuvants in the cutaneous response to antigen after topical vaccination","volume":"29","author":"Himes","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.052_b0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1674-8301(10)60004-8","article-title":"A review of adjuvants for Leishmania vaccine candidates","volume":"24","author":"Mutiso","year":"2010","journal-title":"J Biomed Res"},{"key":"10.1016\/j.vaccine.2018.11.052_b0075","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.4049\/jimmunol.161.7.3211","article-title":"Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge","volume":"161","author":"Glenn","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0080","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/mi.2014.111","article-title":"Cholera toxin adjuvant promotes a balanced Th1\/Th2\/Th17 response independently of IL-12 and IL-17 by acting on Gsalpha in CD11b(+) DCs","volume":"8","author":"Mattsson","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0085","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/jid.2009.247","article-title":"Skin-resident T cells: the ups and downs of on site immunity","volume":"130","author":"Clark","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2016.00151","article-title":"Cutaneous leishmaniasis vaccination: a matter of quality","volume":"7","author":"De Luca","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1034\/j.1600-065X.2000.917307.x","article-title":"The role of nitric oxide in innate immunity","volume":"173","author":"Bogdan","year":"2000","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2018.11.052_b0100","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1084\/jem.194.10.1497","article-title":"The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure","volume":"194","author":"Belkaid","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.11.052_b0105","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri933","article-title":"The immunology of susceptibility and resistance to Leishmania major in mice","volume":"2","author":"Sacks","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0110","first-page":"1032","article-title":"Comparison of in vivo adjuvanticity of liposomal PO CpG ODN with liposomal PS CpG ODN: soluble Leishmania antigens as a model","volume":"15","author":"Golali","year":"2012","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.vaccine.2018.11.052_b0115","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","article-title":"Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major","volume":"186","author":"Gurunathan","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.11.052_b0120","doi-asserted-by":"crossref","DOI":"10.3791\/1980-v","article-title":"In vivo imaging of transgenic Leishmania parasites in a live host","author":"Thalhofer","year":"2010","journal-title":"J Vis Exp: JoVE"},{"key":"10.1016\/j.vaccine.2018.11.052_b0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/expr.2001.4656","article-title":"A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation","volume":"99","author":"Spath","year":"2001","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0130","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.4049\/jimmunol.139.9.3118","article-title":"Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract","volume":"139","author":"Scott","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2008.07.099","article-title":"Identification and characterization of a new Leishmania major specific 3'nucleotidase\/nuclease protein","volume":"375","author":"Lakhal-Naouar","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.11.052_b0140","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0264-410X(99)00233-9","article-title":"Principles of transcutaneous immunization using cholera toxin as an adjuvant","volume":"17","author":"Scharton-Kersten","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.052_b0145","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/CVI.00023-09","article-title":"Cellular and humoral responses to Leishmania major virulence factors in healed cutaneous leishmaniasis and Mediterranean visceral leishmaniasis patients","volume":"16","author":"Lakhal-Naouar","year":"2009","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2018.11.052_b0150","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-3024.1985.tb00098.x","article-title":"A limiting dilution assay for quantifying Leishmania major in tissues of infected mice","volume":"7","author":"Titus","year":"1985","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0155","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.1303145","article-title":"Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana","volume":"193","author":"Dey","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0160","first-page":"24","article-title":"Not all antigens are created equally: progress, challenges, and lessons associated with developing a vaccine for leishmaniasis","author":"Duthie","year":"2017","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2018.11.052_b0165","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1080\/21645515.2016.1171440","article-title":"The success of microneedle-mediated vaccine delivery into skin","volume":"12","author":"Marshall","year":"2016","journal-title":"Human Vaccines Immunotherap"},{"key":"10.1016\/j.vaccine.2018.11.052_b0170","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jconrel.2010.09.018","article-title":"Advances in transcutaneous vaccine delivery: do all ways lead to Rome?","volume":"148","author":"Bal","year":"2010","journal-title":"J Controlled Release: Off J Controlled Release Soc"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.11.052_b0175","first-page":"3","article-title":"The skin as an organ of immunity","volume":"107","author":"Bos","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0180","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/B978-0-12-407679-2.00005-3","article-title":"Mechanisms of immune evasion in leishmaniasis","volume":"82","author":"Gupta","year":"2013","journal-title":"Adv Appl Microbiol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jim.2015.07.010","article-title":"Identification of skin immune cells in non-human primates","volume":"426","author":"Adam","year":"2015","journal-title":"J Immunol Meth"},{"key":"10.1016\/j.vaccine.2018.11.052_b0190","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.nano.2015.12.372","article-title":"Nanoparticulate mediated transcutaneous immunization: myth or reality","volume":"12","author":"Kaurav","year":"2016","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/j.vaccine.2018.11.052_b0195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/CVI.00638-13","article-title":"A nonadjuvanted transcutaneous tetanus patch is effective in boosting anti-tetanus toxoid immune responses","volume":"21","author":"Seid","year":"2014","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2018.11.052_b0200","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.nut.2013.10.003","article-title":"Leishmania donovani: dynamics of L. donovani evasion of innate immune cell attack due to malnutrition in visceral leishmaniasis","volume":"30","author":"Kumar","year":"2014","journal-title":"Nutrition"},{"key":"10.1016\/j.vaccine.2018.11.052_b0205","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1073\/pnas.88.16.7011","article-title":"Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis","volume":"88","author":"Heinzel","year":"1991","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2018.11.052_b0210","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1128\/IAI.67.8.3719-3726.1999","article-title":"Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major","volume":"67","author":"Stacey","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.11.052_b0215","doi-asserted-by":"crossref","first-page":"e1003476","DOI":"10.1371\/journal.ppat.1003476","article-title":"T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine","volume":"9","author":"Schwarz","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.11.052_b0220","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.2008.03705.x","article-title":"Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization","volume":"153","author":"Azeredo-Coutinho","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"13\u201324","key":"10.1016\/j.vaccine.2018.11.052_b0225","first-page":"e4","article-title":"Cutaneous leishmaniasis induces a transmissible dysbiotic skin microbiota that promotes skin inflammation","volume":"22","author":"Gimblet","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2018.11.052_b0230","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1590\/S0100-879X2005000700001","article-title":"What about Th1\/Th2 in cutaneous leishmaniasis vaccine discovery?","volume":"38","author":"Campos-Neto","year":"2005","journal-title":"Brazil J Med Biol Res = Revista Brasileira de Pesquisas Medicas e Biologicas"},{"key":"10.1016\/j.vaccine.2018.11.052_b0235","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.1128\/IAI.73.11.7620-7628.2005","article-title":"Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection","volume":"73","author":"Roberts","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.11.052_b0240","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.20041470","article-title":"A role for IgG immune complexes during infection with the intracellular pathogen Leishmania","volume":"201","author":"Miles","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.11.052_b0245","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.4049\/jimmunol.180.7.4825","article-title":"Leishmania major-specific B cells are necessary for Th2 cell development and susceptibility to L. major LV39 in BALB\/c mice","volume":"180","author":"Ronet","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0250","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/eji.200939455","article-title":"Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation","volume":"40","author":"Deak","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0255","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.4049\/jimmunol.164.7.3681","article-title":"B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology","volume":"164","author":"Smelt","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0260","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2334-5-113","article-title":"Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis","volume":"5","author":"Caldas","year":"2005","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.052_b0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/334255a0","article-title":"Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells","volume":"334","author":"Stevens","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.11.052_b0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.imlet.2005.01.009","article-title":"T helper (h)1\/Th2 and Leishmania: paradox rather than paradigm","volume":"99","author":"Alexander","year":"2005","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2018.11.052_b0275","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1128\/IAI.70.6.2828-2836.2002","article-title":"Vaccination with plasmid DNA encoding TSA\/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB\/c mice","volume":"70","author":"Campos-Neto","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.11.052_b0280","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4049\/jimmunol.166.1.498","article-title":"Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning","volume":"166","author":"Probst","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0285","first-page":"412","article-title":"Immunobiology of leishmaniasis","volume":"47","author":"Sharma","year":"2009","journal-title":"Indian J Exp Biol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0290","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.chom.2013.09.008","article-title":"Photoconvertible pathogen labeling reveals nitric oxide control of Leishmania major infection in vivo via dampening of parasite metabolism","volume":"14","author":"Muller","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2018.11.052_b0295","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1084\/jem.183.4.1501","article-title":"Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase","volume":"183","author":"Stenger","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.11.052_b0300","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1371\/journal.pntd.0000480","article-title":"Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis","volume":"3","author":"Modolell","year":"2009","journal-title":"PLoS NeglTrop Dis"},{"key":"10.1016\/j.vaccine.2018.11.052_b0305","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/eji.200636542","article-title":"Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy","volume":"37","author":"Kropf","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.052_b0310","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/375408a0","article-title":"Altered immune responses in mice lacking inducible nitric oxide synthase","volume":"375","author":"Wei","year":"1995","journal-title":"Nature"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:30:07Z","timestamp":1759401007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18315779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0264410X18315779"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB\/c mice against a Leishmania major challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}